Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

NCT01283139 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01283139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01283139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Lead sponsor
MedImmune LLC
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
April 17, 2014
Enrollment
834 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus